
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The American Journal of Managed Care
almost 27 years ago
The Impact of Health Insurance Market Reforms on Market Competitionalmost 27 years ago
Acne Vulgaris: Pathogenesis and Therapeutic Approachalmost 27 years ago
Parkinson's Disease: Focus on Management Alternativesalmost 27 years ago
The Future of Health Status Assessmentalmost 27 years ago
Regulating the Pharmaceutical Industry: Who Really Benefits?almost 27 years ago
Can Peer-Comparison Feedback Improve Patient Functional Status?almost 27 years ago
Preventive Service Use and Medicaid Managed Care in New York City





